subscribeSubscribe
Marinus lays off 20% to steady ship after IV seizure med issues

Marinus lays off 20% to steady ship after IV seizure med issues
James Waldron FIERCE BIOTECH
08 May 2024
Share Share
Marinus Q1 2024 Results, Business Update On May 8

Marinus Q1 2024 Results, Business Update On May 8
BUSINESSWIRE
01 May 2024
Share Share
Marinus seizure med fails at interim analysis; shares plummet

Marinus seizure med fails at interim analysis; shares plummet

Kevin Dunleavy FIERCE PHARMA
16 Apr 2024
Share Share
Marinus RAISE Update, Prelim Q1 2024 Results

Marinus RAISE Update, Prelim Q1 2024 Results
BUSINESSWIRE
15 Apr 2024
Share Share
Marinus Initiates Global Access Program for ZTALMY Oral Suspension CV

Marinus Initiates Global Access Program for ZTALMY Oral Suspension CV
BUSINESSWIRE
07 Nov 2023
Share Share
Marinus Announces EC Approval of ZTALMY for Epileptic Seizures

Marinus Announces EC Approval of ZTALMY for Epileptic Seizures
BUSINESSWIRE
01 Aug 2023
Share Share
Marinus Announces New Method of Use Patent Granted for IV Ganaxolone

Marinus Announces New Method of Use Patent Granted for IV Ganaxolone
BUSINESSWIRE
21 Jun 2023
Share Share
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY

Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY
BUSINESSWIRE
26 May 2023
Share Share
Marinus Pharmaceuticals Reports Q4 and Full Year 2022 ZTALMY

Marinus Pharmaceuticals Reports Q4 and Full Year 2022 ZTALMY
BUSINESSWIRE
05 Jan 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share